According to a Nasdaq report, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Boehringer Ingelheim’s new type 2 diabetes drug, Synjardy. Synjardy is the latest in a new line of diabetes medications known as sodium-glucose cotransporter-2 inhibitors, called SGLT2 inhibitors for short.
SGLT2 inhibitors help lower patients’ blood sugar by preventing reabsorption of glucose in the kidneys and eliminating excess sugar through ...
continue reading...
Amid recent research linking sodium-glucose cotransporter-2 (SGLT2) inhibitors to diabetic ketoacidosis, Invokana maker Janssen Pharmaceutica has countered with its own report on the new diabetic drug. The study, published in late July by the journal Diabetes Care, claims that incidents of the potentially fatal blood condition are “rare.”
SGLT2 inhibitors are a relatively new class of type 2 diabetes drugs. They work by reducing the amount of glucose reabsorbed in the ...
continue reading...
While sodium-glucose cotransporter-2 (SGLT2) inhibitors draw praise for their weight-loss and blood pressure reduction benefits, medical experts continue to puzzle over their more immediate metabolic and immune system effects. Specifically, researchers are worried about their possible link to diabetic ketoacidosis, a potentially fatal condition caused by excess blood acids, or ketones. In an article published by the Journal of Diabetes Investigation, two Japanese researchers provide a possible explanation for how
continue reading...
Yet another warning regarding dangerous side effects associated with approved medications has been issued by the FDA.
Three specific drugs developed for the treatment of Type-II diabetes have been singled out for their capacity to cause a dangerous blood condition.
Patients taking canagliflozin, dapagliflozin, and empagliflozin should contact their doctors to discuss the possibility of ketoacidosis – a condition where the patient’s body starts producing an overabundance of blood acids. This condition can ...
continue reading...The U.S. Food and Drug Administration (FDA) has issued a Drug Safety Communication warning that the SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin may result in ketoacidosis, a serious blood condition in which the body produces excess blood acids, or ketones. Ketoacidosis may require hospitalization and in extreme cases can prove fatal. The SLGT2 inhibitors are marketed under the brand names Invokana, Invokamet, Farxiga, Jardiance, Glyxambi, and Xigduo ...
